article thumbnail

Sygnature Discovery completes acquisition of SB Drug Discovery to further strengthen its market-leading capabilities

Sygnature Discovery

Sygnature Discovery (“Sygnature”) is delighted to announce the acquisition of SB Drug Discovery, a world leading provider of ion channel and receptor drug discovery research delivering cell line generation and compound screening solutions in neuroscience and other therapeutic indications.

article thumbnail

Target-directed cancer: protein-ligand interactions  

Drug Target Review

Can you elaborate on how these techniques are integrated into your research process and how they contribute to advancing cancer drug discovery? We need to build the assays that we need for compound screening. In 2019 he became Reader in Structural Biology and Cancer Drug Discovery.